Evidence map›Paper›PMID 41551983›Full record

ArticleInternational journal of pharmaceutics: X2026

Catheleeya Mekjaruskul, Andre O'Reilly Beringhs, Tuo Meng, Aji Alex Moothedathu Raynold, Qingguo Xu, Matthew Halquist, Bin Qin, Yan Wang, Xiuling Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Catheleeya MekjaruskulDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Andre O'Reilly BeringhsDivision of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Tuo MengDepartment of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Aji Alex Moothedathu RaynoldDepartment of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Qingguo XuDepartment of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Matthew HalquistDepartment of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Bin QinDivision of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Yan WangDivision of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Xiuling LuDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This investigation compares

Indexed as

DexamethasoneEx vivo ocular permeationIn vitro release testIn vivo ocular pharmacokineticsOphthalmic ointmentTobramycin

Identifiers

PMID41551983
PMCPMC12808560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.